^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    MERTK-targeted antibody-drug conjugate

    Related drugs:
    6ms
    Targeting Myeloid Epithelial Tyrosine Kinase (MERTK) Receptor in Acute Myeloid Leukemia Using a Novel Antibody Drug Conjugate, Rgx-019-MMAE (ASH 2023)
    Finally, we investigated the synergistic effect of RGX-019-MMAE with Venetoclax (BCL2 inhibitor) or 5-Azacytidine in vitro. RGX-019-MMAE significantly induced cell death in AML cell lines and primary AML patient samples. RGX-019-MMAE, combined with chemotherapeutic agents and targeted therapy, produces a synergistic anti-leukemic effect. Our data indicates that MERTK is a potential therapeutic target in AML patients with monocytic subtypes of leukemia.
    IO biomarker
    |
    AXL (AXL Receptor Tyrosine Kinase) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • MERTK (MER Proto-Oncogene, Tyrosine Kinase)
    |
    PTPN11 mutation • MERTK expression
    |
    Venclexta (venetoclax) • azacitidine • RGX-019 • RGX-019-MMAE